{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T01:42:04Z","timestamp":1782265324088,"version":"3.54.5"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. pediatr. gastroenterol. nutr."],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objective:<\/jats:title><jats:p>Post hoc analyses evaluated the effect of infliximab upon concurrent perianal Crohn disease (CD) in a subpopulation of 31 patients from REACH, a randomized trial of 112 children with moderately to severely active luminal CD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods:<\/jats:title><jats:p>The Pediatric Crohn Disease Activity Index perirectal subscore was used to assess perianal symptom activity and therapeutic response. Patients with no symptoms or asymptomatic tags received a score of 0; those with \u201c1\u20132 indolent fistula, scant drainage, no tenderness\u201d received a score of 5; and those with \u201cactive fistula, drainage, tenderness or abscess\u201d received a score of 10. Initial perirectal subscores of 10 or 5 decreasing to 0 were considered complete response. Subscores of 10 decreasing to 5 were considered partial response. All patients were followed for efficacy and safety through week 54.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Twenty\u2010two patients with baseline perianal disease were randomized at week 10 following a 3\u2010dose infliximab induction regimen. At week 2, 40.9% (9\/22) of patients with signs and symptoms of perianal disease at baseline attained response (4 partial and 5 complete). At week 54, 72.7% (16\/22) of patients with signs and symptoms of perianal disease attained response (1 partial and 15 complete). Nine patients developed perianal signs and symptoms during treatment; 7 had complete response and 2 had no response at week 54. The incidence of adverse events for patients with perianal symptoms at baseline and for those in the overall REACH population was similar (95.7% vs 94.6%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Infliximab rapidly reduced concurrent perianal disease signs and symptoms in this REACH cohort.<\/jats:p><\/jats:sec>","DOI":"10.1097\/mpg.0b013e3181a70f21","type":"journal-article","created":{"date-parts":[[2009,7,16]],"date-time":"2009-07-16T07:21:05Z","timestamp":1247728865000},"page":"183-190","source":"Crossref","is-referenced-by-count":52,"title":["Infliximab Therapy in Children With Concurrent Perianal Crohn Disease: Observations From REACH"],"prefix":"10.1002","volume":"49","author":[{"given":"Wallace","family":"Crandall","sequence":"first","affiliation":[{"name":"Nationwide Children's Hospital Columbus OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Hyams","sequence":"additional","affiliation":[{"name":"Connecticut Children's Center Hartford USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subra","family":"Kugathasan","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin Milwaukee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Hospital for Sick Children University of Toronto Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Zrubek","sequence":"additional","affiliation":[{"name":"Centocor Inc Malvern PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Olson","sequence":"additional","affiliation":[{"name":"RW Johnson Pharmaceutical Research and Development La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Liu","sequence":"additional","affiliation":[{"name":"RW Johnson Pharmaceutical Research and Development Titusville NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Heuschkel","sequence":"additional","affiliation":[{"name":"Addenbrooke's Hospital Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Markowitz","sequence":"additional","affiliation":[{"name":"North Shore\u2010Long Island Jewish Health System New Hyde Park NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Cohen","sequence":"additional","affiliation":[{"name":"Children's Center for Digestive Health Care Atlanta GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harland","family":"Winter","sequence":"additional","affiliation":[{"name":"MassGeneral Hospital for Children Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gigi","family":"Veereman\u2010Wauters","sequence":"additional","affiliation":[{"name":"Queen Paola Children's Hospital Antwerp Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Ferry","sequence":"additional","affiliation":[{"name":"Texas Children's Hospital Houston USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N","family":"Baldassano","sequence":"additional","affiliation":[{"name":"Children's Hospital of Philadelphia Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.03.022"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2004.01.002"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-2931"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e3282ef4426"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000217769.83142.c6"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2007.07.156"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastro.2003.08.025"},{"key":"e_1_2_6_9_1","first-page":"922","article-title":"Perianal Crohn's disease in children and adolescents","volume":"91","author":"Tolia V","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_10_1","first-page":"699","volume-title":"Inflammatory Bowel Diseases","author":"Griffiths AM","year":"2003"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03578.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200004000-00018"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)91160-8"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70251-3"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.11.014"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.12.003"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1536-4801.1991.tb10268.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1536-4801.1992.tb10528.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20767"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000237933.38223.da"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1536-4801.2004.tb12290.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.04083.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02060.x"},{"key":"e_1_2_6_27_1","first-page":"44","article-title":"Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition","volume":"88","author":"Markowitz J","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mib.0000235103.47280.bb"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mib.0000232470.00703.67"}],"container-title":["Journal of Pediatric Gastroenterology and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1097\/MPG.0b013e3181a70f21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T12:09:14Z","timestamp":1705579754000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1097\/MPG.0b013e3181a70f21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1097\/MPG.0b013e3181a70f21"],"URL":"https:\/\/doi.org\/10.1097\/mpg.0b013e3181a70f21","archive":["Portico"],"relation":{},"ISSN":["0277-2116","1536-4801"],"issn-type":[{"value":"0277-2116","type":"print"},{"value":"1536-4801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}